Generated by AI
Equillium Inc. is a clinical-stage biotechnology company focused on developing therapies for severe autoimmune and inflammatory disorders with high unmet medical need. Its current pipeline centers on immunology programs designed to modulate disease-driving immune pathways, including monoclonal antibody and cytokine-inhibitor approaches aimed at conditions such as graft-versus-host disease, lupus nephritis, ulcerative colitis, alopecia areata, and other immune-mediated diseases. The company’s work spans immuno-inflammatory areas across transplant science, gastroenterology, rheumatology, dermatology, oncology, and related specialty care segments. Equillium Inc. operates as a research-driven biopharmaceutical business, advancing novel therapeutic candidates through clinical development and strategic collaborations to address complex diseases where existing treatment options remain limited. Headquartered in La Jolla, California, Equillium Inc. plays a focused role in the biotechnology market as a developer of targeted immune-modulating medicines.
Website2223 Avenida De La Playa
La Jolla, CA, 92037
United States
The latest articles about EQ.
Summary of Dec 22's posts. Generated by AI.
Summary of Sep 9's posts. Generated by AI.
Summary of Aug 27's posts. Generated by AI.
Investors talking about EQ also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.